Login to Your Account

Eyetech Locates 'Exit' Through $935M Cash, Stock OSI Merger

By Karen Pihl-Carey

Tuesday, August 23, 2005
As potential eye drug competitor Lucentis nears market, Eyetech Pharmaceuticals Inc. agreed to merge with OSI Pharmaceuticals Inc., bringing along its approved product Macugen, in a deal worth $935 million - or $20 a share, a 43 percent premium over Eyetech's closing stock price on Friday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription